© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Biomarker-Driven Lung Cancer
Responses Observed With Poziotinib in HER2-Positive Non-Small Cell Lung Cancer
July 28, 2020
"We believe that poziotinib is a significant advancement for patients with this deadly disease in an area of high unmet medical need."
Pyrotinib Induces Antitumor Activity in HER2-Positive Non-Small Cell Lung Cancer
July 14, 2020
In a single-arm phase 2 clinical trial, pyrotinib had promising antitumor activity as treatment of patients with HER2-positive non–small cell lung cancer.
Adherence to NCCN Guidelines for Biomarker Testing Shows Decreased Risk of Mortality for Non-Squamous aNSCLC
June 12, 2020
The NCCN guidelines recommend biomarker testing as a part of the pathologic evaluation for patients with non-squamous advanced NSCLC and NCC set out to determine how these guidelines decrease the incidence of mortality.
Pembrolizumab Deemed Active Treatment for Brain Metastasis in NSCLC
April 15, 2020
Brain metastasis responses were elicited from treatment with pembrolizumab in patients with non–small cell lung cancer, in a PD-L1–positive cohort of a phase II clinical trial conducted by researchers at Yale Cancer Center. According to a YCC press release, pembrolizumab prolonged overall survival with limited toxicity in these patients.
FDA Clears IND for Novel Immunotherapy in Solid Tumors
April 15, 2020
The FDA has provided clearance to an Investigational New Drug application for GT103 for the treatment of solid tumors. A phase I clinical trial will be initiated to evaluate this novel targeted immunotherapy in patients with refractory non–small cell lung cancer, announced Grid Therapeutics, LLC.
Frontline Tislelizumab Combination Significantly Improves PFS in Nonsquamous NSCLC
April 14, 2020
The combination of tislelizumab, a PD-L1 antibody, pemetrexed and platinum-based chemotherapy achieved a statistically significant prolongation in progression-free survival compared with pemetrexed and platinum chemotherapy alone as first-line treatment of patients with nonsquamous non–small cell lung cancer, meeting the primary end point of a phase III BGB-A317-304 trial.
A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
April 14, 2020
A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
Options for Patients With Lung Cancer and Genetic Alterations
April 11, 2020
Luis E. Raez, MD, discusses targeted therapies for patients with lung cancer who have genetic alterations.
FDA Grants Priority Review to BLA for First-Line Nivolumab/Ipilimumab Plus Limited Chemo in NSCLC
April 08, 2020
The FDA has accepted the Biologics License Application for and granted Priority Review to the combination of nivolumab plus ipilimumab with limited chemotherapy as a first-line treatment of patients with metastatic or recurrent non–small cell lung cancer who have no EGFR or ALK genomic tumor aberrations, according to a press release from Bristol Myers Squibb. The Prescription Drug Free User Act target action date is set as August 6, 2020, and the combination was granted Fast Track designation.
Research on Molecular Mutations Guides Use of Targeted Therapies in Lung Cancer
April 08, 2020
In an interview with Targeted Oncology, James A. Reeves, MD, discussed how targeted therapies are being used presently in lung cancer and the potential of these agents in the future.